Shattuck Labs, Inc.

Shattuck Labs, Inc.

STTK·NASDAQ

$4.80

-1.4%
HealthcareBiotechnology

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

At a Glance

Live Snapshot
Market Cap$229.94M
EPS-0.7000
P/E Ratio-6.86
Earnings Date08/06/2026

sttk

Acquisitions (Net)

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Shattuck Labs, Inc.

Shattuck Labs, Inc. Competitors Analysis of Acquisitions (Net)

STTK · NASDAQ
CompanyAcquisitions (Net)
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
IMA logo
ImageneBio Inc
NASDAQ:IMA
-5.21M
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
155.00K
N/AN/AN/A
101.29M
N/A32.1%N/A
37.00K
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
Shattuck Labs, Inc.

Shattuck Labs, Inc. Fair Value Envelope

STTK · NASDAQ

Our analysis suggests that STTK has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.8, this represents a potential HIDDEN relative to our calculated worth for Shattuck Labs, Inc..

Intrinsic Value
Current Price: $4.8